Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

Main Article Content

Matthias Augustin
Jolanta Weglowska
Mark Lebwohl
Carle Paul
Vincent Piquet
Howard Sofen
Andrew Blauvelt
Daniel Burge
Luke Peterson
Janice Drew
Robert Rollen

Keywords

certolizumab, psoriasis, clinical trial

Abstract

Abstract Not Available

 

Disclosure: Study supported by Dermira.